13F Holdings
中文EN

INFU InfuSystem Holdings, Inc

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1337013 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.4%
TTM net income YoY70.9%
TTM EPS YoY69.2%
Revenue 3-yr CAGR5.5%
Net income 3-yr CAGR118.3%

Margins

Gross margin57.6%
Operating margin9.8%
Net margin6.5%
FCF margin17.1%
EBITDA margin18.8%

Returns

ROE15.8%
ROA9.3%
ROIC (approx.)13.4%
Asset turnover1.42x

Leverage & solvency

Liabilities / assets38.6%
Debt / equity0.31x
Current ratio2.68x
Interest coverage13.83x

Cash quality & payout

Operating cash flow / net income2.67x
Accruals ratio-15.5%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$143.44M$134.86M$125.78M$109.91M$102.38M
Cost of revenue$63.14M$64.46M$62.68M$49.35M$43.85M
Gross profit$80.30M$70.40M$63.11M$60.56M$58.54M
SG&A expense$56.97M$51.21M$45.38M$44.15M$40.68M
Operating income$11.92M$6.89M$4.09M$1.65M$2.82M
Interest expense$1.30M$1.78M$2.17M$1.40M$1.38M
Pretax income$10.62M$5.06M$1.85M$130,000$1.26M
Income tax$4.00M$2.71M$979,000$112,000-$163,000
Net income$6.63M$2.35M$872,000$18,000$1.42M
EBITDA$25.21M$19.39M$16.60M$15.01M$17.45M
EPS (basic)0.320.110.040.000.07
EPS (diluted)0.310.110.040.000.06
Weighted avg. shares (diluted)21.10M21.71M21.65M21.55M22.05M
Balance sheet
Cash & equivalents$3.19M$527,000$231,000$165,000$186,000
Receivables$22.90M$21.20M$19.83M$16.87M$15.40M
Inventory$5.39M$6.53M$6.40M$4.82M$3.94M
Current assets$36.34M$32.16M$30.62M$24.78M$22.07M
PP&E, net$3.36M$4.03M$4.32M$4.38M$4.52M
Goodwill$3.71M$3.71M$3.71M$3.71M$3.71M
Intangibles$6.87M$6.46M$7.45M$8.44M$10.93M
Total assets$100.56M$103.61M$102.92M$99.39M$97.59M
Current liabilities$20.18M$17.66M$15.71M$14.47M$12.90M
Short-term debt$0$0$0$0$349,000
Long-term debt$19.62M$23.86M$29.10M$33.16M$32.75M
Total debt$19.62M$23.86M$29.10M$33.16M$33.10M
Total liabilities$43.23M$46.09M$50.61M$51.38M$49.31M
Shareholders' equity$57.33M$57.53M$52.30M$48.00M$48.27M
Net debt$16.44M$23.34M$28.87M$32.99M$32.91M
Shares outstanding20.21M21.27M21.20M20.78M20.70M
Cash flow statement
Operating cash flow$24.41M$20.46M$11.22M$17.52M$18.32M
Capital expenditure$560,000$1.09M$1.02M$982,000$980,000
Free cash flow$23.85M$19.37M$10.20M$16.54M$17.34M
Investing cash flow-$6.79M-$13.24M-$6.73M-$11.48M-$21.32M
Financing cash flow-$14.96M-$6.92M-$4.42M-$6.06M-$6.46M
Depreciation & amortization$13.29M$12.50M$12.51M$13.36M$14.62M
Stock-based compensation$4.36M$4.46M$4.07M$3.83M$6.40M
Share buybacks$9.87M$1.18M$153,000$5.46M$560,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.